Search tips
Search criteria

Results 1-5 (5)

Clipboard (0)

Select a Filter Below

Year of Publication
Document Types
author:("Rida, masimal")
1.  Effect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates 
Lang Kuhs, Krystle A. | Porras, Carolina | Schiller, John T. | Rodriguez, Ana Cecilia | Schiffman, Mark | Gonzalez, Paula | Wacholder, Sholom | Ghosh, Arpita | Li, Yan | Lowy, Douglas R. | Kreimer, Aimée R. | Poncelet, Sylviane | Schussler, John | Quint, Wim | van Doorn, Leen-Jan | Sherman, Mark E. | Sidawy, Mary | Herrero, Rolando | Hildesheim, Allan | Safaeian, Mahboobeh | Lang Kuhs, Krystle A. | Schiller, John T. | Schiffman, Mark | Wacholder, Sholom | Lowy, Douglas R. | Kreimer, Aimée R. | Sherman, Mark E. | Hildesheim, Allan | Safaeian, Mahboobeh | Porras, Carolina | Rodriguez, Ana Cecilia | Gonzalez, Paula | Herrero, Rolando | Gonzalez, Paula | Herrero, Rolando | Ghosh, Arpita | Li, Yan | Poncelet, Sylviane | Schussler, John | Quint, Wim | van Doorn, Leen-Jan | Sidawy, Mary | Self, Steve | Benavides, Adriana | Calzada, Luis Diego | Karron, Ruth | Nayar, Ritu | Roach, Nancy | Cain, Joanna | Davey, Diane | DeMets, David | Fuster, Francisco | Gershon, Ann | Holly, Elizabeth | Raventós, Henriette | Rida, Wasima | Rosero-Bixby, Luis | Suthers, Kristen | Lara, Silvia | Thomas, Sarah | Alfaro, Mario | Barrantes, Manuel | Concepción Bratti, M. | Cárdenas, Fernando | Cortés, Bernal | Espinoza, Albert | Estrada, Yenory | González, Paula | Guillén, Diego | Herrero, Roland | Jiménez, Silvia E. | Morales, Jorge | Villegas, Luis | Morera, Lidia Ana | Pérez, Elmer | Porras, Carolina | Rodríguez, Ana Cecilia | Rivas, Libia | Freer, Enrique | Bonilla, José | García-Piñeres, Alfanso | Silva, Sandra | Atmella, Ivannia | Ramírez, Margarita | Hildesheim, Allan | Kreimer, Aimée R. | Lowy, Douglas R. | Macklin, Nora | Schiffman, Mark | Schiller, John T. | Sherman, Mark | Solomon, Diane | Wacholder, Sholom | Pinto, Ligia | Kemp, Troy | Eklund, Claire | Hutchinson, Martha | Sidawy, Mary | Quint, Wim | van Doorn, Leen-Jan
American Journal of Epidemiology  2014;180(6):599-607.
Two trials of clinically approved human papillomavirus (HPV) vaccines, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE I/II) and the Papilloma Trial Against Cancer in Young Adults (PATRICIA), reported a 22% difference in vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 2 or worse in HPV-naïve subcohorts; however, serological testing methods and the HPV DNA criteria used to define HPV-unexposed women differed between the studies. We applied previously described methods to simulate these HPV-naïve subcohorts within the Costa Rica HPV16/18 Vaccine Trial and assessed how these criteria affect the estimation of VE. We applied 2 enzyme-linked immunosorbent assay (ELISA) thresholds for HPV16 and HPV18 seropositivity (8 and 7 ELISA units/mL, respectively, for PATRICIA; 54 and 65 ELISA units/mL, respectively, for FUTURE I/II (to approximate the competitive Luminex immunoassay)) and 2 criteria for HPV DNA positivity (12 oncogenic HPV types, plus HPV66 and 68/73 for PATRICIA; or plus HPV6 and 11 for FUTURE I/II). VE was computed in the 2 naïve subcohorts. Using the FUTURE I/II and PATRICIA criteria, VE estimates against cervical intraepithelial neoplasia grade 2 or worse, regardless of HPV type, were 69.0% (95% confidence interval: 40.3%, 84.9%) and 80.8% (95% confidence interval: 52.6%, 93.5%), respectively (P = 0.1). Although the application of FUTURE I/II criteria to our cohort resulted in the inclusion of more sexually experienced women, methodological differences did not fully explain the VE differences.
PMCID: PMC4157699  PMID: 25139208
human papillomavirus; methodological differences; naïve population; vaccine efficacy
2.  Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines 
Reduced antituberculosis drug concentrations may contribute to unfavorable treatment outcomes among HIV-infected patients with more advanced immune suppression, and few studies have evaluated pharmacokinetics of the first-line antituberculosis drugs in such patients given fixed-dose combination tablets according to international guidelines using weight bands. In this study, pharmacokinetics were evaluated in 60 patients on 4 occasions during the first month of antituberculosis therapy. Multilevel linear mixed-effects regression analysis was used to examine the effects of age, sex, weight, drug dose/kilogram, CD4+ lymphocyte count, treatment schedule (5 versus 7 days/week), and concurrent antiretrovirals (efavirenz plus lamivudine plus zidovudine) on the area under the concentration-time curve from 0 to 12 h (AUC0-12) of the respective antituberculosis drugs and to compare AUC0-12s at day 8, day 15, and day 29 with the day 1 AUC0-12. Median (range) age, weight, and CD4+ lymphocyte count were 32 (18 to 47) years, 55.2 (34.4 to 98.7) kg, and 252 (12 to 500)/μl. For every 10-kg increase in body weight, the predicted day 29 AUC0-12 increased by 14.1% (95% confidence interval [CI], 7.5, 20.8), 14.1% (95% CI, −0.7, 31.1), 6.1% (95% CI, 2.7, 9.6) and 6.0% (95% CI, 0.8, 11.3) for rifampin, isoniazid, pyrazinamide, and ethambutol, respectively. Males had day 29 AUC0-12s 19.3% (95% CI, 3.6, 35.1) and 14.0% (95% CI, 5.6, 22.4) lower than females for rifampin and pyrazinamide, respectively. Level of immune suppression and concomitant antiretrovirals had little effect on the concentrations of the antituberculosis agents. As they had reduced drug concentrations, it is important to review treatment responses in patients in the lower weight bands and males to inform future treatment guidelines, and revision of doses in these patients should be considered.
PMCID: PMC3370773  PMID: 22411614
3.  AIDS Vaccines and Preexposure Prophylaxis: Is Synergy Possible? 
While the long-term goal is to develop highly effective AIDS vaccines, first generation vaccines may be only partially effective. Other HIV prevention modalities such as preexposure prophylaxis with antiretrovirals (PrEP) may have limited efficacy as well. The combined administration of vaccine and PrEP (VAXPREP), however, may have a synergistic effect leading to an overall benefit that is greater than the sum of the individual effects. We propose two test-of-concept trial designs for an AIDS vaccine plus oral or topical ARV. In one design, evidence that PrEP reduces the risk of HIV acquisition is assumed to justify offering it to all participants. A two-arm study comparing PrEP alone to VAXPREP is proposed in which 30 to 60 incident infections are observed to assess the additional benefit of vaccination on risk of infection and setpoint viral load. The demonstrated superiority of VAXPREP does not imply vaccine alone is efficacious. Similarly, the lack of superiority does not imply vaccine alone is ineffective, as antagonism could exist between vaccine and PrEP. In the other design, PrEP is assumed not to be in general use. A 2 × 2 factorial design is proposed in which high-risk individuals are randomized to one of four arms: placebo vaccine given with placebo PrEP, placebo vaccine given with PrEP, vaccine given with placebo PrEP, or VAXPREP. Between 60 and 210 infections are required to detect a benefit of vaccination with or without PrEP on risk of HIV acquisition or setpoint viral load, with fewer infections needed when synergy is present.
PMCID: PMC3101085  PMID: 21043994
4.  Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm▿ † 
Journal of Virology  2009;83(14):7337-7348.
The development of a rapid and efficient system to identify human immunodeficiency virus type 1 (HIV-1)-infected individuals with broad and potent HIV-1-specific neutralizing antibody responses is an important step toward the discovery of critical neutralization targets for rational AIDS vaccine design. In this study, samples from HIV-1-infected volunteers from diverse epidemiological regions were screened for neutralization responses using pseudovirus panels composed of clades A, B, C, and D and circulating recombinant forms (CRFs). Initially, 463 serum and plasma samples from Australia, Rwanda, Uganda, the United Kingdom, and Zambia were screened to explore neutralization patterns and selection ranking algorithms. Samples were identified that neutralized representative isolates from at least four clade/CRF groups with titers above prespecified thresholds and ranked based on a weighted average of their log-transformed neutralization titers. Linear regression methods selected a five-pseudovirus subset, representing clades A, B, and C and one CRF01_AE, that could identify top-ranking samples with 50% inhibitory concentration (IC50) neutralization titers of ≥100 to multiple isolates within at least four clade groups. This reduced panel was then used to screen 1,234 new samples from the Ivory Coast, Kenya, South Africa, Thailand, and the United States, and 1% were identified as elite neutralizers. Elite activity is defined as the ability to neutralize, on average, more than one pseudovirus at an IC50 titer of 300 within a clade group and across at least four clade groups. These elite neutralizers provide promising starting material for the isolation of broadly neutralizing monoclonal antibodies to assist in HIV-1 vaccine design.
PMCID: PMC2704778  PMID: 19439467
5.  Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa 
AIDS (London, England)  2013;27(17):2775-2786.
To describe immunologic, virologic, and clinical HIV disease progression by HIV-1 subtype among Africans with well documented estimated dates of HIV infection (EDIs).
Prospective cohort.
Adults and youth with documented HIV-1 infection in the past 12 months were recruited from seroincidence cohorts in East and Southern Africa and followed at 3–6 month intervals. Blood for lymphocyte subset and viral load determination was collected at each visit. Pol was sequenced from the first positive specimen to ascertain subtype. Preantiretroviral therapy disease progression was measured by three time-to-event endpoints: CD4+ cell count 350 cells/μl or less, viral load measurement at least 1 × 105 copies/ml, and clinical AIDS.
From 2006 to 2011, 615 participants were enrolled at nine research centers in Kenya, Rwanda, South Africa, Uganda, and Zambia; 579 (94.1%) had viral subtyping completed. Predominant subtypes were C (256, 44.2%), A (209, 36.1%), and D (84, 14.5%). After adjustment for age, sex, and human leukocyte antigen alleles in Cox regression analyses, subtype C-infected participants progressed faster than subtype A to all three endpoints [CD4+ hazard ratio 1.60, 95% (confidence interval) CI 1.16, 2.20; viral load hazard ratio 1.59, 95% CI 1.12, 2.25; and AIDS hazard ratio 1.60, 95% CI 1.11, 2.31). Subtype D-infected participants reached high viral load more rapidly (hazard ratio 1.61, 95% CI 1.01, 2.57) and progressed nearly twice as fast to AIDS compared to subtype A (hazard ratio 1.93, 95% CI 1.21, 3.09).
Subtype-specific differences in HIV disease progression suggest that the local subtype distribution be considered when planning HIV programs and designing and defining clinical endpoints for HIV prevention trials.
PMCID: PMC3815107  PMID: 24113395
Africa; AIDS; CD4+ cell count; HIV disease progression; HIV-1 subtype; HIV-serodiscordant couples; men who have sex with men; viral load

Results 1-5 (5)